

## Chronic obstructive pulmonary disease (COPD) Committee meeting

**Date:** 14/11/2018

**Location:** London

**Minutes:** Approved

<b>Committee members present:</b>	
Andrew Molyneux (Chair)	Present for items 1–6
Katy Beckford	Present for items 1–6
Lauren Hogg	Present for items 1–6
Nick Hopkinson	Present for items 1–6
Karen O’Hara	Present for items 1–6
Tony Perkins	Present for items 1–6
Luisa Pettigrew	Present for items 1–6
Ravijyot Saggu	Present for items 1–6
Karen Sennett	Present for items 1–6
Alan Thomas	Present for items 1–6

<b>In attendance:</b>	
Joe Crutwell Technical Analyst	Present for items 1–6
Clare Dadswell Technical Analyst	Present for items 1–6
James Hall Medical Editor	Present for items 1–6
Marie Harrisingh Technical Adviser	Present for items 1–6
Ben Johnson Senior Technical Analyst (HE)	Present for items 1–6
Anneka Patel Project Manager	Present for items 1–6

**Observing:** Adrian Jonas (NICE)

## Committee minutes – COPD meeting 11

<b>Apologies:</b>	
Louise Restrick	Committee member
Sarah MacFadyen	Committee member

### **1. Welcome and objectives for the meeting**

The Chair welcomed the committee members and attendees to the additional meeting on chronic obstructive pulmonary disease (COPD).

The Chair informed the committee of apologies as listed above.

The Chair asked everyone to verbally declare any new interests arising since the last meeting. No new declarations were made.

The Chair and a senior member of the Developer's team noted that the interests declared previously did not prevent the attendees from fully participating in the meeting.

It was noted that the objectives of this meeting were to discuss updated clinical evidence and health economics for triple therapy and corticosteroids in relation to COPD. This additional work will publish as an addendum to the updated guideline in June 2019.

### **2. In people with stable COPD, what is the clinical and cost effectiveness of a LAMA plus a LABA plus ICS compared with:**

- a LABA plus an inhaled corticosteroid (ICS)
- a LAMA plus LABA

Clare Dadswell, Technical analyst, presented the clinical evidence for this question and Ben Johnson, Senior technical analyst presented the health economic model for this question.

### **3. Draft recommendations**

The committee discussed the evidence presented and drafted two new recommendations and amended one existing recommendation.

### **4. Are shorter durations of $\leq 7$ days of corticosteroid treatment effective at treating acute exacerbations in people with COPD compared to longer treatments of $> 7$ days?**

Joe Crutwell, Technical analyst presented the clinical evidence for this question.

## Committee minutes – COPD meeting 11

The committee discussed the evidence presented and drafted one new recommendation.

### **5. Summary of meeting**

Marie Harrisingh, Technical adviser, gave a summary of the meeting and next steps.

### **6. AOB**

Anneka Patel gave an overview of key dates and next steps to committee members. The chair thanked the committee for attending and confirmed the date of the next meeting (see below).

**Next meeting:** Wednesday, 20<sup>th</sup> March at 10am – 5pm in NICE London offices